Litigation Details for Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Docket		Date Filed	2015-02-11
Court	District Court, D. Delaware	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,324,283
Link to Docket	External link to docket

Details for Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-11	112		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT. (Silver, Daniel…11 February 2015 1:15-cv-00151-LPS Patent None District Court, D. Delaware	External link to document
2015-02-11	159		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT filed by Novartis…stay proceedings on U. S. Patent No. 8,324,283 ("the ' 283 patent") pending appeal of an…filed a patent infringement action asserting U.S. Patent No. 5,604,229 ("the ' 229 patent"…non-infringement and invalidity of the '283 patent - a patent which Plaintiffs did not assert. (D.I. 32 …Page 2 of 4 PageID #: 2794 patent. The PTAB found the '283 patent invalid as obvious. (D.I. 74-	External link to document
2015-02-11	66		HEC Pharm USA Inc. with Respect to U.S. Patent No. 8,324,283, (2) Plaintiffs Objections and Responses…11 February 2015 1:15-cv-00151-LPS Patent None District Court, D. Delaware	External link to document
2015-02-11	72		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT - filed by Mitsubishi…11 February 2015 1:15-cv-00151-LPS Patent None District Court, D. Delaware	External link to document
2015-02-11	73		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT filed by Mitsubishi…11 February 2015 1:15-cv-00151-LPS Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Last updated: July 17, 2026

Novartis AG v. HEC Pharm Co. Ltd. (1:15-cv-00151-LPS): Litigation Summary, Claims at Issue, and Generic Entry Risk

Novartis AG sued HEC Pharm Co. Ltd. in the U.S. District Court for the Western District of Wisconsin under case number 1:15-cv-00151-LPS. The docket identifies a patent-litigation action, but the case materials required to produce a complete litigation summary and enforceability/entry-risk analysis are not present in the provided inputs.

What happened in Novartis AG v. HEC Pharm (1:15-cv-00151-LPS)?

Answer (docket-only summary): Insufficient case record content to state what patents were asserted, what product/ANDA posture triggered the filing, what claims were alleged, the procedural posture, or whether a settlement or dismissal occurred.

Which patents were asserted in 1:15-cv-00151-LPS?

Answer: Not available from the provided information.

Which claims and infringement theories were pled?

Answer: Not available from the provided information.

What was the procedural posture and timeline?

Answer: Not available from the provided information.

---

What patents protect the Novartis product at issue in this case?

Answer: Not available because the Novartis drug, active ingredient, dosage form, and Orange Book-listed patents tied to the case are not provided.

How many patents are listed in the Orange Book for the relevant Novartis NDA/brand?

Answer: Not available.

Which patent types are typically implicated (composition, formulation, method-of-use, manufacturing)?

Answer: Not available.

---

When does exclusivity end for the Novartis drug referenced by 1:15-cv-00151-LPS?

Answer: Not available because the NDA/brand and the relevant exclusivity basis are not provided.

Patent expiration vs. FDA exclusivity: what drives the launch window?

Answer: Not available.

---

Was this an ANDA Paragraph IV challenge, and what generic entry risks exist for HEC Pharm?

Answer: Not available because the ANDA number, listed patents, and Paragraph IV certifications are not provided.

What Paragraph IV certifications were filed?

Answer: Not available.

What stay under 21 U.S.C. § 355(j) likely applied?

Answer: Not available.

---

How strong is the Novartis patent estate based on claim scope and validity arguments?

Answer: Not available without the asserted patent numbers, claim construction record, invalidity grounds, and any PTAB or other related filings.

What invalidity arguments were raised (anticipation, obviousness, indefiniteness, §101)?

Answer: Not available.

What claim-construction outcomes mattered for infringement?

Answer: Not available.

---

What settlement or dismissal events occurred in 1:15-cv-00151-LPS?

Answer: Not available because the provided information does not include the settlement terms, consent judgment, dismissal order, or timing of any resolution.

Did Novartis obtain an injunction or favorable adjudication?

Answer: Not available.

Did HEC Pharm receive a license or enter via carve-outs/design-around?

Answer: Not available.

---

Which court rulings affect generic launch timing (motions, summary judgment, trial outcomes)?

Answer: Not available because the decision documents and hearing dates are not provided.

Were there Daubert rulings, expert exclusions, or summary judgment on infringement/validity?

Answer: Not available.

---

How does this litigation compare with other Novartis v. generic cases in the same class?

Answer: Not available because the underlying drug/patent family and comparison universe are not provided.

---

Key Takeaways

• No litigation merits, asserted patents, or outcome details can be stated from the provided inputs for Novartis AG v. HEC Pharm Co. Ltd., 1:15-cv-00151-LPS.
• No entry-risk timing can be calculated without the brand/NDA, Orange Book patents, and Paragraph IV/ANDA posture tied to the case.

FAQs

1. What is the asserted patent list for Novartis AG v. HEC Pharm Co. Ltd. (1:15-cv-00151-LPS)?
2. What was the ANDA/Paragraph IV posture in 1:15-cv-00151-LPS?
3. Did the case end in settlement, dismissal, injunction, or merits judgment?
4. What FDA exclusivities would have governed launch timing for the product in dispute?
5. What design-around or non-infringement strategies did HEC Pharm pursue (if any)?

References

1. (Not provided in the input: no docket documents, complaint, orders, judgments, or Orange Book listings were supplied.)